Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227326 · ClinicalTrials.gov registry record · Phase 1
AOH1996 for the Treatment of Refractory Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
- 2
- Study locations
NCT05227326 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 92 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05227326, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG PCNA Inhibitor AOH1996
Study Locations (2)
Arizona
- Honor Health Research and Innovation Institute - Scottsdale
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2029-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227326
The ClinicalTrials.gov registry entry for NCT05227326 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which PCNA Inhibitor AOH1996 is the first listed.
NCT05227326 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05227326 about?
NCT05227326 is a clinical study titled "AOH1996 for the Treatment of Refractory Solid Tumors". This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT05227326?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2022-08-12. Estimated completion is 2029-09-13.
What conditions does trial NCT05227326 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Malignant Solid Neoplasm, Osteosarcoma.
What interventions are being tested in trial NCT05227326?
The interventions under investigation include: PCNA Inhibitor AOH1996 (DRUG).
Who is sponsoring clinical trial NCT05227326?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227326 being conducted?
This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.